EuroPCR 2017 Symposium

on .

Protecting the Brain; While Treating the Heart | Sponsored by Keystone Heart 
Wednesday 17 May 2017 | 13:35-14:35 Room 352B

Attend this session if you want to: 
• Understand the clinical need for cerebral embolic protection during cardiovascular procedures 
• Learn about the clinical evidence surrounding cerebral embolic protection and the clinical experience with the TriGuard tm device 
• Realise the economic impact of cerebral embolic events

13:35 Session objectives - M. Mack 
13:40 New scientific guidelines NeuroARC - study - A. Lansky 
13:52 Discussion and audience interaction 
13:57 Keystone Heart clinical experience and evidence - R. Makkar 
14:09 Discussion and audience interaction 
14:14 Cost benefit analysis of cerebral embolic protection - J. Moses
14:26 Discussion and audience interaction 
14:31 Session evaluation and key learnings – P. Stella

We hope to see you there!
The TriGuard Cerebral Protection Device is not commercially available in the USA.